A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Inscopix Announces Collaboration With Bruker for Advanced Analysis of Brain Circuits by Combining Miniature Microscopes With Multiphoton Microscopy

Inscopix today announced a collaboration with Bruker Corporation (NASDAQ: BRKR) for its new Multimodal Image Registration and Analysis (MIRA) platform.

Inscopix notes the platform and the collaboration will empower brain researchers to catalyze a more precise and comprehensive mechanistic understanding of the brain by seamlessly integrating one-photon imaging of neuronal activity using Inscopix’s miniature microscope-based nVistaTM and nVokeTM systems, with high-resolution and multi-color imaging of diverse cell-types and pathologies in the brain via Bruker’s Ultima multiphoton microscopes.

“We are very excited to announce the launch of the MIRA platform and the collaboration with Bruker, a leader in multiphoton imaging-based applications for neuroscience,” said Kunal Ghosh, Ph.D., CEO and founder of Inscopix. “This partnership with Bruker is a key part of our strategy to work with partners in the neuroscience imaging industry to help researchers record, align, register and correlate changes in neural activity in a defined population of neurons with changes in other brain cell-types and pathologies.”

“Inscopix’s MIRA platform is an important innovation that will, when used in conjunction with our Ultima multiphoton microscopy, combine the many advantages of one-photon and multiphoton imaging, while overcoming previous technological limitations, for a richer and more sophisticated understanding of the brain,” added Xiaomei Li, Ph.D., VP, and GM of Bruker’s Fluorescence Microscopy Business. “We are always seeking out important collaborations with technological leaders, such as Inscopix, to help make functional brain imaging more routine and widespread in the neuroscience research community.”

The MIRA platform is designed such that researchers can first image large-scale brain activity at single-cell resolution in freely-behaving animal subjects, an important benefit of Inscopix. Then, researchers can image the same field-of-view in the brain with multiphoton and confocal microscopes at higher resolution and at multiple wavelengths, an important advantage of Bruker, but which requires animal immobilization. The MIRA platform thus allows researchers to gain greater insights from cells of interest through dual-color imaging and the ability to compare calcium activity between freely-behaving and head-fixed conditions by providing a solution for co-registering cells from both modalities.

The companies will be co-marketing the Inscopix MIRA platform with Bruker’s multiphoton microscopes. The combined solution includes an adapter to integrate Inscopix miniscope data from freely-moving animals with multicolor laser scanning microscope data from the head-fixed animals, along with an Inscopix-developed software solution to streamline co-registering of images obtained from both modalities.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy